Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
CTKB Stock Chart & Stats
$5.39
-$0.08(-1.16%)
At close: 4:00 PM EST
$5.39
-$0.08(-1.16%)
Day’s Range― - ―
52-Week Range$2.37 - $7.30
Previous CloseN/A
Volume141.86K
Average Volume (3M)1.42M
Market Cap
$681.52M
Enterprise Value$216.02M
Total Cash (Recent Filing)$261.73M
Total Debt (Recent Filing)$35.16M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 04, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding127,864,830
10 Day Avg. Volume1,789,917
30 Day Avg. Volume1,415,913
Financial Highlights & Ratios
PEG Ratio2.89
Price to Book (P/B)2.14
Price to Sales (P/S)4.23
P/FCF Ratio38.79
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit2.05
Enterprise Value/Ebitda-11.91
Forecast
1Y Price Target
$5.83Price Target Upside8.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$196.35M
Bulls Say, Bears Say
Bulls Say
Market LeadershipCytek remains a leader in the flow cytometry market and continues to take share.
Product LaunchThe company launched a new instrument, the Cytek Aurora Evo system, which offers improvements relative to their flagship Aurora, and feedback has been positive.
Revenue GrowthRecurring revenue maintained positive momentum, with both services and consumables growing 18% year over year.
Bears Say
Geopolitical And Economic HeadwindsMultiple ongoing headwinds, such as NIH budgets, China, tariffs, and biopharma funding, continue to impact revenues and margins this year.
Market ContractionRecent spending trends suggest the flow cytometry market itself may be contracting or at least stagnating.
Uncertain Growth PathThe path back to growth remains uncertain as does the potential timeline for when the CapEx cycle will reinvigorate organic growth.
Cytek Biosciences News
CTKB FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was $2.37 and its highest was $7.30 in the past 12 months.
What is Cytek Biosciences’s market cap?
Cytek Biosciences’s market cap is $681.52M.
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is Mar 04, 2026 which is in 90 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on Nov 05, 2025. The company reported $0.004 earnings per share for the quarter, beating the consensus estimate of -$0.03 by $0.034.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is -0.02.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 127,864,830 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of $0.004 in its last earnings report, beating expectations of -$0.03. Following the earnings report the stock price went up 13.217%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Currently, no hedge funds are holding shares in CTKB
Cytek Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.83 (8.16% Upside)
$5.83 (8.16% Upside)
Blogger Sentiment
Bullish
CTKB Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 325.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.37%
12-Months-Change
Fundamentals
Return on Equity
-3.36%
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Company Description
Cytek Biosciences
Cytek Biosciences (CTKB) is a biotechnology company that specializes in providing advanced flow cytometry solutions for researchers and clinicians in the life sciences sector. The company focuses on developing innovative products that enhance the capabilities of flow cytometry, enabling more precise and efficient cellular analysis. Key offerings include its Aurora and Northern Lights product lines, which are designed for multi-parameter analysis of cells, as well as software solutions that facilitate data analysis and interpretation.
CTKB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixture of positive and negative elements. While there are significant achievements in revenue growth in APAC, service, and reagent sectors, challenges remain in the EMEA region and the U.S. academic and government sectors. Increased operating expenses and a net loss also weigh negatively, balancing out the positive aspects.View all CTKB earnings summariesCTKB Stock 12 Month Forecast
Average Price Target
$5.83
▲(8.16% Upside)
Technical Analysis
Ownership Overview
9.17% Insiders
13.70% Mutual Funds
16.90% Other Institutional Investors
42.07% Public Companies and
Individual Investors